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Fetal & Neonatal Outcomes of the Magnesium Sulfate and 
Nefidipine in Suppression of Preterm Labor 
Abstract 
Objectives: Preterm Labor occurs in 11.8% of all pregnancies 
and  is  the  most  etiology  of  Neonatal  morbidity  without 
Anomalies and after intra partum congenital Anomalies is the 
second etiology of Neonatal mortality that has high economic & 
psychiatric  cost.  Premature  infants  have  Neurotic 
complications  and  they  are  week  about  physical  growth, 
practical  cognitive  and  lesson  tasks.  One  of  usage  drugs  in 
prevention of preterm labor is Nefidipin.  
Materials and Methods: This research is a Double blind RCT. All 
of pregnant mothers with 26-34 weeks with signs of preterm 
labor have come to Alzahra & Talegani hospitals were research 
population. Research samples were 80 pregnant women that 
have  eligibility  criteria  and  treated  with  Sulphate  mg  & 
Nefidipin. Samples allocated randomly in 2 groups by use of 
rand list soft ware and block of 3 and 6.In group A were  used 
Sulphate mg 4 g first and then 2g/h for 48 h and group B were 
used  Nefidipin 20 mg first and 20 mg /half h after. Success of 
treatment was measured by Partograph & checklist .Data was 
analyzed by statistic tests and spss ver. 13.  
Results: Neonatal complications such as 1 min Apgar and 5 min 
Apgar score, Sao2 and ABG in 2 groups, that treatment could 
not prevent contractions, have not significantly different. But 
there were significant different about Fetal complications such 
as bit to bit variation, decrease of fetal movement and dropt of 
base line of FHR (p≤ 0.05). 
Conclusion: Data showed that Nefidipine was more effective in 
comparison of Sulphate mg in suppress of uterus contractions 
and improve of feto-Neonatal outcomes that these will prevent 
further Growth & Development complications in Neonatal and 
this drug can be best supplement for Sulphate mg in suppress 
of preterm contractions of uterus. 
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Introduction:  
Nowadays the rate of premature birth called 
“preterm  labor”  is  high  causing  many 
problems for both the mother and the baby 
(1).  Preterm  labor  is  the  leading  cause  of 
death in a newborn without anomalies. After 
birth defects, premature labor is the second 
main  cause  of  neonates’  mortality.  This 
imposes a high economic and psychological 
cost to the society (2). Preterm labor occurs 
in 11.8% of various races (3). Babies born 
before  24  weeks  gestation  do  not  survive 
and the ones who survive are less likely to be 
healthy and are at increased risk of health 
problems  (4).  It  also  increases  the  risk of 
respiratory distress syndrome (RDS) among 
these  group  caused  by  lack  of  surfactants 
secretion.  However  fetus  at  26-34  weeks 
that complete dosage of betamethasone 48h 
before  delivery,  the  mortality  and  RDS 
morbidity rates are significantly decreased. 
Antenatal glucocorticoid administration can 
significantly reduce RDS and other problems 
including  intra  ventricular  hemorrhage 
(IVH),  patent  ductus  arteriosus  (PDA), 
pneumothorax, necrotizing enter colitis (5).  
Infants born preterm are at risk of various 
neurological  complications. 
Neurodevelopment  squeal  in  preterm 
infants  include  cerebral  palsy,  seizures, 
hydrocephalus,  blindness,  deafness  and 
cognitive impairment. The risk of an adverse 
outcome  increases  with  decreasing 
gestational age at birth (2). Early morbidity 
and prognostic variables that contribute to 
adverse  neurodevelopment  outcomes  are 
include:  grades  3-4  intraventricular 
hemorrhage,  necrotizing  entro  colitis, 
periventricular  leukomalacia,  neonatal 
infections  and  Broncopulmonary  dysplasia 
(6).  At  school  age  VLBW  newborns  have 
poorer  physical  growth  and  cognitive 
function as well as school performance (3).  
The final goal of treating preterm labor is to 
prolong  of  pregnancy  in  the  patients  and 
delay  delivery  for  at  least  48  hours  so  it 
allows corticosteroid treatment to improve 
fetal lung maturity (1). Much research has 
been conducted regarding the prevention of 
or  minimizing  the  complication  of 
premature  labor.  Various  treatments  have 
also  been  proposed  among  this  group  of 
patients.  Although  pharmacological 
suppression  of  contractions  is  the  most 
common  treatment  (7),  there  is  still 
disagreement  on  the  best  method  of 
treatment.  Some  pharmacological 
compounds  are  used  to  suppress  uterine 
contractions in women with preterm labor 
(8). 
 The  medicines  used  to  suppress  preterm 
labor  are  including  Ritodrine,  Magnesium 
sulfate  and  Calcium  channel  blockers  (1). 
The effects of relaxant agents in suppression 
of preterm labor has not been proven, yet 
(9).  Preterm  labor  is  the  main  reason  for 
early death among 85% of premature infants 
(10). previous studies about this subject and 
necessity  of  this  study  is  to  compare  the 
effects of magnesium sulfate and nefidipine 
to suppress preterm labor. We also evaluate 
fetal  and  neonatal  complications  due  to 
magnesium  sulfate  and  nefidipine 
administration. 
Material & Methods: 
This was a double-blind, randomized clinical 
trial  conducted  in  Alzahra  and  Taleghani 
Medical  Educational  Centers  in  Tabriz. 
Research samples were 80 pregnant women 
that allocated randomly in 2 groups by use of 
rand  list  soft  ware  and  block  of  3  and 
6.Inclusion criteria's  included  women with 
gestational  age  of  26 -34  weeks  having 
regular uterine contractions lasted about 20-
30 seconds, at least one contraction every 10 
minutes,  with  cervical  dilation  of 
(maximum)  2-3  cm,  cervical  effacement  of 
50% or less, feeling of pressure in the pelvis, 
low  back  pain  and  vaginal  discharge. 
Entering  the  labor  room  written  informed 
consent  was  taken  by  the  all  participants. 
For the women in magnesium sulfate group 
an  initial  loading  dose  of  4g  was  given 
intravenously  and  then 2g  every  one  hour 
provided that a patellar reflex was present, 
urine output during the proceeding half an 
hour exceeds 30 ml, and respiration exceeds 
12  per  minute.  For  the  patients  in  the 
nefidipine group initially received 20 mg of 
oral nefidipine, 20mg nefidipine was given 
again if the contractions continued after half 
an  hour.  If  not,  subsiding  20  mg  was 
continually administered every 3-8 hours up 
to 48 hours. Treatments were discontinued  F Fartash et al 
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if  contractions  progressed.  The 
contraindications  of  administration  of 
nefidipine  included:  maternal  hypotension 
(systolic  BP  less  than  9mmHg),  Liver 
dysfunction,  recent  intake  of  magnesium 
sulfate.  The  data  from  the  study  were 
analyzed  using  statistical  descriptive 
method (frequency, percentage and mean± 
standard  deviation),  statistical  tests 
(independent  sample  t-test),        and  Chi-
square  test.  In  this  study  P<0.05  was 
considered statistically significant. 
Results: 
In the magnesium sulfate group, decreasing 
the frequency of fetal movement was 27.5%. 
While  heart  rate  reduction  from  baseline 
was  57.5%  and  fetal  heart  rate  exchanges 
was  decreased  in  37.5%.  None  of  these 
changes were seen in the nefidipine group. 
Comparison showed significant difference in 
fetal  heart  rate  and  reduction  of  fetal 
movement,  changes  in  baseline  state  and 
heart rate changes. (Table - 1)  
No  significant  difference  in  neonatal 
outcomes  was  showen  between  the  two 
groups  (the  first  and  fifth  minute  Apgar 
score,  admission  to  NICU,  Sao2,  PH,  PCO2, 
PO2, HCO2, BE). (Table - 2) 
Discussion: 
Results  of  the  study  showed  that  the 
significant differences in the drug effects on 
fetal  movement  as  well  as  baseline  fetal 
heart rate. In the magnesium sulfate group 
the  baseline  fetal  heart  rate  (signed  in 
monitoring device) dropped by 10-20 beats. 
In addition, the heart rate changes were less 
than the fetal heart rate, appears similar to 
sinusoidal  pattern.  Hallak  et  al  (1999) 
conducted  a  study  titled:  “The  effects  of 
magnesium  sulfate  on  fetal  heart  rate 
parameters”.  Findings  showed  that 
magnesium sulfate administration resulted 
in decreased fetal heart rate baseline values 
and  variability  which  was  consistent  with 
the  present  study  (11).  According  to  the 
results of a study by Fujimori et al (2004), 
“The  effects  of  magnesium  sulfate  on 
behavioral  activities  of  fetal  goats”, 
incidence  of  fetal  heart  rate  accelerations 
during  magnesium  sulfate  infusion  was 
significantly decreased, that these are also 
consistent  with  the  current  study  (12). 
Regarding  arterial  blood  gas  (ABG) 
measurement,  there  was  no  significant 
statistical difference between two groups in 
the  first  and  fifth    minute  Apgar  score, 
admission to NICU, Oxygen saturation, PH, 
CO2,  PO,  HCO3,  BE.  Edwin  &  Sabaratnam 
(2005)  reviewed  12  researches  and  then 
published an article titled: “Recent advances 
in  management  of  preterm  labor”.  They 
concluded that calcium channel blockers can 
reduce the incidence of respiratory distress 
syndrome,  necrotizing  enter  colitis, 
intraventricular  hemorrhage  and  neonatal 
jaundice.  In  this  study  magnesium  sulfate 
infusion resulted in high fetal complications 
(6).  These  results  are  consistent  with  our 
findings. This difference is from the fact that, 
in our study ABG was only measured in those 
neonates  who  had  failed  treatment  and 
delivery  was  unavoidable.  Before 
completion  of  Betamethason  intake,  all  of 
the  21  preterm  neonates  were  born. 
Therefore, all of them were admitted to NICU 
with respiratory distress syndrome. But in 
the study by Edwin et al, all of the newborns 
were  assessed  after  birth  regardless 
whether born before or after completion of 
Betamethasone intakes. 
Conclusion : 
In  this  study  we  compared  effects  of 
magnesium  sulfate  and  nefidipine  for 
suppress of preterm labor. Findings showed 
that  nefidipine  was  more  efficient  than 
magnesium  sulfate  in  suppress  of  uterin e 
contractions.  Yet,  nefidipine  is  associated 
with improved fetal and neonatal outcomes 
such as fetal heart rate and fetal movement, 
changes  in  baseline  state  and  heart  rate 
changes compared to the magnesium sulfate 
agent; thus the difference is significant. We 
suggest that nefidipine use for suppression 
of preterm labors in Hospitals. 
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Table 1:   Comparison of fetal outcomes of the study groups separately. 
 
 
Variables 
 
Groups 
 
 
 
P 
Magnesium sulfate  Nefidipine 
Reduction  No change  Reduction  No change   
Fetal 
movement  11(27.5)  29(72.5)  0(0)  40(100)  <0.001 
Fetal baseline 
heart rate  23(57.5)  17(42.5)  0(0)  40(100)  <0.001 
Fetal heart 
rate changes  15(37.5)  25(62.5)  0(0)  40(100)  <0.001 
 
 
 
 
Table 2 : Neonatal characteristics.                
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
 
Groups 
 
 
 
P 
Magnesium sulfate  Nefidipine 
First minute Apgar score  7.38±1.07  5.6±1.51  0.7 
Fifth minute Apgar 
score 
8.47±1.12  8.8±1.3  0.57 
Admission to NICU  1±0.001  0.8±0.44  0.37 
 
 
Neonatal 
ABG 
SaO2(%)  80.04±17.65  85±13.5  0.56 
PH  6.35±2.35  6.16±2.56  0.87 
PCO2(%)  31.95±1.8  30.3±2  0.86 
PO2(%)  28.69±2.32  30.54±2.77  0.87 
HCO3  17.77±7.2  14.9±7.67  0.43 
BE  -2.9±5.7  -4±1.73  0.69  F Fartash et al 
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